Type 2 diabetes represents one of the most significant public health crises in contemporary Quebec. It is estimated that about one million Quebecers currently live with diagnosed diabetes, and several hundred thousand others have it without knowing it - type 2 diabetes can progress silently for 5 to 10 years before significant symptoms appear or a diagnosis is made. In parallel, a considerable proportion of the adult Quebec population is in a prediabetic state - fasting blood glucose between 6.1 and 6.9 mmol\/L or impaired glucose tolerance - a state that often precedes overt diabetes and is highly reversible through lifestyle changes.<\/p>\n
The human cost of uncontrolled type 2 diabetes is considerable: cardiovascular complications\u2014myocardial infarction, stroke\u2014diabetic nephropathy leading to chronic kidney failure and dialysis, diabetic retinopathy, the leading cause of acquired blindness in adults, peripheral neuropathy, and diabetic foot. The good news is that these complications are largely preventable through early screening, structured management, and maintaining satisfactory glycemic control. Clinique Omicron offers health check-ups, including diabetes and prediabetes screening, at several of its Quebec locations, allowing for early detection and proactive management before complications arise.<\/p>\n
Diabetes Canada recommends screening for type 2 diabetes for all adults aged 40 and over, every 3 years in the absence of risk factors, and more frequently for those with high-risk factors. The CANRISK score - the Canadian Diabetes Risk Assessment Questionnaire - identifies high-risk individuals for earlier and more frequent screening. Key risk factors include : overweight and obesity, particularly abdominal obesity - waist circumference greater than 94 cm in men and 80 cm in women -, first-degree family history of type 2 diabetes, membership of certain higher-risk ethnic communities - Aboriginals, South Asians, Afro-Caribbeans, Latin Americans -, a history of gestational diabetes or birth of a macrosomic child, polycystic ovary syndrome, high blood pressure, dyslipidemia - low HDL and high triglycerides -, and smoking.<\/p>\n
Sedentary lifestyles and high-energy-density diets are major modifiable risk factors\u2014addressing them represents the most powerful preventive lever available. In individuals with prediabetes, intervention studies have demonstrated that a lifestyle modification program\u2014a loss of 5 to 7 %of body weight combined with at least 150 minutes of moderate physical activity per week\u2014reduces the progression to type 2 diabetes by 58 %, which is more effective than metformin alone in randomized trials. Early screening therefore makes it possible to identify the window of preventive intervention where it is most effective.<\/p>\n
The screening and diagnosis of type 2 diabetes rely on three main blood tests. Fasting blood glucose\u2014measured after a fast of at least 8 hours\u2014is the simplest and most commonly used screening test. A value below 6.0 mmol\/L is normal, between 6.1 and 6.9 mmol\/L indicates impaired fasting glucose, which is indicative of prediabetes, and 7.0 mmol\/L or higher on two separate occasions establishes a diagnosis of diabetes. Glycated hemoglobin\u2014HbA1c\u2014reflects the average blood glucose level over the past 2 to 3 months and allows for screening without prior fasting, making it more convenient in a clinical setting. An HbA1c between 6.0 and 6.4 % falls within the prediabetic range, and 6.5 % or higher on two occasions confirms diabetes.<\/p>\n
Oral glucose tolerance testing \u2014 OGTT \u2014 involves measuring blood glucose 2 hours after ingesting 75 g of dissolved glucose. It is the most sensitive test for detecting glucose intolerance and certain forms of diabetes not detected by fasting blood glucose or HbA1c. It is particularly useful when monitoring post-gestational diabetes, in the assessment of metabolic syndrome, or when other tests are discordant. The RAMQ covers diabetes screening tests according to medical indications \u2014 fasting blood glucose, HbA1c, and OGTT are accessible with a medical request. The comprehensive health assessments offered at Clinique Omicron systematically integrate these markers into the evaluated metabolic profile, allowing for structured screening even in asymptomatic patients.<\/p>\n
The management of type 2 diabetes has evolved considerably over the past decade with the introduction of new therapeutic classes with demonstrated benefits beyond glycemic control alone. Treatment goals aim to maintain an HbA1c below 7.0 % for the majority of patients \u2014 a goal personalized according to age, comorbidities, and life expectancy \u2014 to prevent microvascular and macrovascular complications, and to improve quality of life. Metformin remains the cornerstone of first-line pharmacological treatment due to its efficacy, well-established safety profile, lack of hypoglycemia in monotherapy, and low cost.<\/p>\n
SGLT-2 inhibitors\u2014empagliflozin, dapagliflozin, canagliflozin\u2014and GLP-1 receptor agonists\u2014semaglutide, liraglutide, dulaglutide\u2014have demonstrated cardiovascular and renal benefits in large randomized studies, independent of glycemic control, positioning them as preferred treatments for diabetic patients at high cardiovascular risk or with established diabetic nephropathy. Structured monitoring of diabetic patients includes quarterly HbA1c measurement, annual lipid profile, urine albumin-to-creatinine ratio and creatinine for renal monitoring, annual fundus examination by an ophthalmologist, annual podiatric examination, and blood pressure monitoring at each visit. This rigorous monitoring is offered at Clinique Omicron as part of preventive medicine and chronic disease management.<\/p>\n
Can type 2 diabetes be reversed or only managed?<\/strong><\/p>\n The terminology of \u2019reversal\u00ab or \u00bbremission\u00ab of type 2 diabetes has been the subject of much clinical discussion, particularly following the publication of the DIRECT and Look AHEAD studies, which demonstrated that significant weight loss can lead to normalization of blood glucose levels in certain diabetic patients. According to the new consensus definitions adopted by learned societies, remission of type 2 diabetes is defined as an HbA1c below 6.5 % maintained for at least 3 months without antidiabetic pharmacotherapy. It is achievable in a subset of patients - particularly those with a recent diagnosis, an HbA1c not too high at baseline, and a substantial weight loss of 10 to 15 % or more. The most effective interventions to achieve remission are bariatric surgery - remission rates of 50 to 80 % at 1 year -, intensive lifestyle intervention programs with significant caloric restriction, and medically supervised very low-energy hypocaloric diets. Remission is not permanent and requires maintenance of lifestyle modifications - weight regain usually leads to diabetes relapse.<\/p>\n What is the difference between type 1 and type 2 diabetes?<\/strong><\/p>\n Both forms of diabetes share the common feature of chronic hyperglycemia, but their pathophysiological mechanisms, patient profiles and treatments are fundamentally different. Type 1 diabetes is an autoimmune disease - the immune system destroys the insulin-producing beta cells of the pancreas, leading to absolute insulin deficiency. It occurs most often in children, adolescents and young adults, requires lifelong insulin therapy and accounts for around 10 % of all cases of diabetes. Type 2 diabetes, by far the most frequent with 90 % of cases, results from a combination of insulin resistance - cells respond less well to insulin - and a progressive failure of pancreatic beta cells to compensate for this resistance by increased secretion. It generally occurs after the age of 40, is strongly associated with overweight and a sedentary lifestyle, and can be managed initially without insulin by lifestyle modifications and oral medication, although insulin therapy becomes necessary in some patients as the disease progresses.<\/p>\n How often should a diabetic patient see their doctor?<\/strong><\/p>\n The frequency of medical consultations for the follow-up of type 2 diabetes depends on the level of glycemic control, the stability of the clinical situation, and the comorbidities present. In general, Diabetes Canada guidelines recommend a medical consultation every 3 months for patients whose diabetes is not controlled to target, or whose treatment has recently been modified, to assess HbA1c and adjust management. When control is stable and satisfactory - HbA1c at target for more than 6 months - a frequency of 6-monthly visits may be appropriate, with a full annual check-up including all elements of complication monitoring. In addition to scheduled medical visits, home capillary blood glucose monitoring - the frequency of which is adapted according to the type of treatment and level of control - enables the patient and his or her doctor to monitor progress between consultations. At Clinique Omicron, diabetic patients can benefit from structured follow-up coordinated by their doctor, with access to on-site blood sampling and referral to specialists - endocrinologist, ophthalmologist, podiatrist, nutritionist - according to needs identified during follow-up.<\/p>\n